Drugs / anti-nf-P2X7
anti-nf-P2X7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02587819 | May → Oct 2013 | skin basal cell carcinoma | Biosceptre | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-nf-P2X7 | “The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration.” NCT02587819 ↗ |
| Known as | BSCT | “The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration.” NCT02587819 ↗ |
| Known as | BSCT (anti-nf-P2X7) 10% Ointment | “BSCT (anti-nf-P2X7) 10% Ointment” NCT02587819 ↗ |
| Modality | Protein / enzyme biologic | “anti-nf-P2X7 (highly purified sheep IgG)” NCT02587819 ↗ |
| Route | Topical | “in an ointment formulation for topical administration” NCT02587819 ↗ |